Corrigendum to: American Burn Association 53rd Annual Meeting

Association of American Medical Colleges annual meeting and annual report.

American Association for the Study of Liver Diseases--53rd Annual Meeting. 1-5 November 2002, Boston, MA, USA.

Liver transplantation has revolutionized the care of patients with end-stage liver disease. Liver transplantation is indicated for acute or chronic liver failure from any cause. Because there are no randomized controlled trials of liver transplantation versus no therapy, the efficacy of this surgery is best assessed by carefully comparing postoperative survival with the known natural history of...

34th annual san antonio breast cancer symposium and 53rd american society of hematology annual meeting and exposition.

domized registration trial, 808 patients (mean age, 54 years) received either placebo plus trastuzumab (an 8-mg/kg loading dose, followed by a 6-mg/kg maintenance dose) plus docetaxel (Taxotere, Sanofi) (75 mg/m2, escalating to 100 mg/m2 if tolerated, for six cycles or more, as recommended) or pertuzumab (an 840-mg loading dose, followed by a 420-mg maintenance dose) plus trastuzumab (an 8-mg/k...

62nd annual meeting of the american association for the study of liver diseases and american college of rheumatology annual meeting.

daily. Patients receiving alisporivir as IFN-free treatment who achieved undetectable HCV–RNA levels (below 25 IU/mL) at week 4 continued with initial treatment. Patients with detectable HCV–RNA levels were given add-on IFN and continued with ALV plus PR triple therapy from week 6 to week 24. Dr. Pawlotsky reported a greater than 3 log reduction in mean HCV–RNA levels over the first 4 weeks wit...

The American Association for Cancer Research Annual Meeting.

5669: 8:00 a.m. 12:00 p.m. Presenter: Joseph Buggy, Ph.D., Pharmacyclics, Inc. "Our strong presence at the AACR meeting highlights the breadth of our product portfolio in cancer and autoimmune diseases," said Richard A. Miller, M.D., president and chief executive officer of Pharmacyclics. "In addition to data on our HDAC inhibitor, other presentations describe our Factor VIIa and Btk inhibitors...